LPL Financial’s Lucid Diagnostics LUCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$198K Buy
172,376
+30,985
+22% +$39.4K ﹤0.01% 5499
2025
Q4
$154K Buy
141,391
+212
+0.2% +$237 ﹤0.01% 5524
2025
Q3
$143K Buy
141,179
+110,900
+366% +$121K ﹤0.01% 5437
2025
Q2
$34.8K Buy
30,279
+100
+0.3% +$129 ﹤0.01% 5409
2025
Q1
$45K Sell
30,179
-23,212
-43% -$27.9K ﹤0.01% 5163
2024
Q4
$43.7K Buy
53,391
+12,035
+29% +$10.6K ﹤0.01% 5113
2024
Q3
$33.7K Sell
41,356
-101
-0.2% -$83 ﹤0.01% 5040
2024
Q2
$34K Buy
41,457
+4,425
+12% +$3.75K ﹤0.01% 4888
2024
Q1
$30K Buy
37,032
+4,402
+13% +$5.71K ﹤0.01% 4812
2023
Q4
$46K Buy
32,630
+4,230
+15% +$5.58K ﹤0.01% 4659
2023
Q3
$33.2K Buy
28,400
+14,000
+97% +$20.3K ﹤0.01% 4563
2023
Q2
$20K Hold
14,400
﹤0.01% 4516
2023
Q1
$20.2K Hold
14,400
﹤0.01% 4409
2022
Q4
$19.6K Hold
14,400
﹤0.01% 4369
2022
Q3
$22K Hold
14,400
﹤0.01% 4318
2022
Q2
$33K Buy
+14,400
New +$32K ﹤0.01% 4285

Other funds holding LUCD

LPL Financial's LUCD Position: Q1 2026 in Review

LPL Financial increased its Lucid Diagnostics (LUCD) stake by 22% in Q1 2026, buying an estimated $39.4K and bringing the position to 172,376 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #5499.

LPL Financial first reported a position in LUCD in Q2 2022 and has held it in 16 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • LPL Financial held 172,376 shares of Lucid Diagnostics worth $198K as of Q1 2026.
  • LPL Financial bought 30,985 Lucid Diagnostics shares in Q1 2026, an estimated $39.4K.
  • Lucid Diagnostics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5499 holding.
  • LPL Financial first reported a position in Lucid Diagnostics in Q2 2022 and has held it in 16 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.